Immunocore Holdings plc Financial Liabilities At Amortised Cost
Immunocore Holdings plc (IMCR) had Financial Liabilities At Amortised Cost of GBP 40.98 million as of 2022-12-31, per its 20-F filed 2023-03-01.
Discontinued › Notes
ifrs-full:FinancialLiabilitiesAtAmortisedCost · last filed 2023-03-01
- 2022-12-31: Financial Liabilities At Amortised Cost 40.98M GBP.
- 2021-12-31: Financial Liabilities At Amortised Cost 37.23M GBP; Financial Liabilities At Amortised Cost as first filed 69.62M GBP.
- 2020-12-31: Financial Liabilities At Amortised Cost 61.74M GBP.
- 2019-12-31: Financial Liabilities At Amortised Cost 39.86M GBP.
| Period end | Financial Liabilities At Amortised Cost | Financial Liabilities At Amortised Cost as first filed |
|---|---|---|
| 2022-12-31 | 40.98M GBP 20-F · filed 2023-03-01 | |
| 2021-12-31 | 37.23M GBP 20-F · filed 2023-03-01 | 69.62M GBP 20-F · filed 2022-03-03 |
| 2020-12-31 | 61.74M GBP 20-F · filed 2022-03-03 | |
| 2019-12-31 | 39.86M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |